8 research outputs found
A Critique of Antinomies as Justification for the Usual Interpretation of Kant’s Epistemology
No full textTranscendentalna idealnost predmeta naše spoznaje bitna je sastavnica Kantove
epistemologije — barem njezine uobičajene interpretacije. U članku se tvrdi da
(upravo zbog teze o transcendentalnoj idealnosti) uobičajena interpretacija Kantove
epistemologije (UIKE) plauzibilno pati od problema nekoherencije i nije
jasno opravdana. Na tvrdnju da antinomije daju opravdanje za UIKE u članku
se odgovara da bi onda barem jedna antinomija morala biti racionalno–kompulzivna.
Međutim nijedna nije. Stoga se zaključuje kako UIKE nije opravdana
antinomijama i — ako su antinomije jedino opravdanje za UIKE — onda ona
nije opravdana.The transcendental ideality of the objects of cognition is an essential part of Kant’s
epistemology — at least, in its usual interpretation. In this article, the author proposes
that (precisely because of the transcendental ideality thesis), the usual interpretation
of Kant’s epistemology (UIKE) suffers from problems of incoherence, and
plausibly so, and so is not clearly justified. In response to the suggestion that antinomies
justify UIKE, the author claims that at least one antinomy should then be
rationally compulsive, however, not one of them is. The author, therefore, concludes
that antinomies do not justify UIKE and, that if antinomies are the only justification
for UIKE, then it is not justified
Measuring Readability of Farm Information Published in Newspapers
No full textPrint media have been accepted as an important means of communication. Printed words are effective as compared to other mass media because they hold certain merits. These words help the communicator to think, organize ideas and choose better so that the reader can understand the ideas easily (Salunkhe and Sawant, 1984). Printed words are largely used for communicating useful farm information to literate farmers, thus catering to the needs of farming communities. Printed material is being used increasingly with steady improvement in literacy rate in the country (Anonymous, 2002
Outcome of patients with HTLV-1-associated adult T-cell leukemia-lymphoma after SCT: a retrospective study by the EBMT LWP
No full text12 months had chronic GVHD. Overall these results indicate that allo-SCT but not auto-SCT may salvage a subset of ATL patients, supporting the existence of graft vs ATL effect also in non-Japanese patients.Bone Marrow Transplantation advance online publication, 14 July 2014; doi:10.1038-bmt.2014.143.Bazarbachi A, 2010, J CLIN ONCOL, V28, P4177, DOI 10.1200-JCO.2010.28.0669; Bazarbachi A, 2004, LANCET ONCOL, V5, P664, DOI 10.1016-S1470-2045(04)01608-0; Bazarbachi A, 2011, BLOOD, V118, P1736, DOI 10.1182-blood-2011-03-345702; Fukushima T, 2005, LEUKEMIA, V19, P829, DOI 10.1038-sj.leu.2403682; Hermine O, 1998, BIODRUGS, V10, P447, DOI 10.2165-00063030-199810060-00003; Hishizawa M, 2010, BLOOD, V116, P1369, DOI 10.1182-blood-2009-10-247510; Hodson A, 2011, J CLIN ONCOL, V29, P4696, DOI 10.1200-JCO.2011.35.5578; Ishida T, 2013, BIOL BLOOD MARROW TR, V19, P1731, DOI 10.1016-j.bbmt.2013.09.014; Itonaga H, 2013, BLOOD, V121, P219, DOI 10.1182-blood-2012-07-444372; Kami M, 2003, BRIT J HAEMATOL, V120, P304, DOI 10.1046-j.1365-2141.2003.04054.x; Marcais A, 2012, LEUK RES TREATMENT, V2012; Okamura J, 2005, BLOOD, V105, P4143, DOI 10.1182-blood-2004-11-4193; Phillips AA, 2009, LEUKEMIA LYMPHOMA, V50, P1039, DOI 10.1080-10428190902887571; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073-pnas.77.12.7415; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111-j.1365-2141.1991.tb08051.x; Takasaki Y, 2010, BLOOD, V115, P4337, DOI 10.1182-blood-2009-09-242347; Tsukasaki K, 2009, J CLIN ONCOL, V27, P453, DOI 10.1200-JCO.2008.18.2428; Tsukasaki K, 2007, J CLIN ONCOL, V25, P5458, DOI 10.1200-JCO.2007.11.9958; Tsukasaki K, 1999, BONE MARROW TRANSPL, V23, P87, DOI 10.1038-sj.bmt.1701533; Uike N, 2011, RETROVIROLOGY, V8, pA33; Utsunomiya A, 2001, BONE MARROW TRANSPL, V27, P15, DOI 10.1038-sj.bmt.1702731; YAMAMOTO N, 1982, INT J CANCER, V30, P289, DOI 10.1002-ijc.29103003060
FOG-1, a transcriptional regulator within the haematopoietic system
No full textFriend of GATA-1 (FOG-1) is a member of the friend of GATA (FOG)
family of proteins, which consists of large multitype zinc finger cofactors that
bind to the amino zinc finger of GATA transcription factors and modulate their
activity. FOG-1 also interacts with the C-terminal binding protein (CtBP),
mainly known as a corepressor and the nucleosome remodelling and histone
deacetylase repressive (NuRD) complex ; thus, integrating FOG-1 into the
transcription factor and chromatin modifier networks. Remarkably, the protein
activates or represses gene transcription by facilitating binding of GATA
factors to DNA, recruiting chromatin remodelling complexes, or by stabilizing
tissue-specific chromatin loops. Physical interaction between FOG and GATA
proteins in vivo is essential for the development of a broad array of tissues,
reflecting the overlapping expression patterns of these factors. Notably, within
the haematopoietic system, FOG-1 is absent in most of the myeloid lineages ;
it is expressed at high level in multipotent progenitors, erythroid and
megakaryocytic cells, low level in lymphoid and haematopoietic stem cells.
The cofactor is essential for differentiation of the erythroid and
megakaryocytic lineages, notably by interacting with GATA-1. FOG-1 also
plays a role in the T-lineage by repressing GATA-3 dependent induction of
Th2 development. Interestingly, overexpression of FOG-1 in avian
eosinophils, which do not normally express FOG-1, reprograms these
differentiated cells into multipotent cells. To study FOG-1 in mammals, we
used a novel transgenic mouse model strategy which we had designed to
generate mice with conditional overexpression of FOG-1. Our work with
enforced expression of FOG-1 in the whole murine haematopoietic system led
to a reduction in the number of circulating eosinophils, confirming and
extending to mammals the previously reported role of FOG-1 in repressing
this lineage development. Strikingly, we have identified the expression of
FOG-1 in early B lymphocytes, but not in late developmental stages such as
mature B cells and plasma cells. Moreover, FOG-1 function had never been
described in the B-lineage, where GATA factors are not expressed. Therefore,
we were intrigued by both the regulated expression of FOG-1 during B cell
development and its molecular mechanism of action in the absence of GATA
factors. Thus, we generated transgenic mice in which FOG-1 expression was
enforced at a physiologically relevant level in the B lymphoid system : in
mature B cells and from early B cell stages. We found that sustained FOG-1
expression in mature and late B cells did not affect their development or
function, contrary to our expected hypothesis. Although the mice
overexpressing FOG-1 from early B cell lineages showed only a weak
phenotype, we extensively studied FOG-1 partners in early B cell stages.
Indeed, describing FOG-1 molecular mechanism of action in the absence of
GATA factors is a question that warrant further investigation. We notably
found FOG-1 in complex with Ikaros, a transcription factor well described as
crucial for B cell development. The cofactor was also found associated to the
CtBP and NuRD epigenetic complexes in B cell lines
Therapeutic options for adult T-cell leukemia-lymphoma
No full textAdult T-cell leukemia-lymphoma (ATL) is the first human malignancy associated with a retroviral infection and occurs in approximately 5 percent of the 15 million to 20 million people infected by human T-cell lymphotropic virus 1. In general, ATL is resistant to chemotherapy, and while awaiting new therapeutics, patients commonly face a detrimental progress of the disease and death. The viral oncoprotein Tax is a key player in the cause of ATL and acts by interfering with DNA repair, cell cycle, apoptosis, and proliferative cellular programs. The Shimoyama classification describes four different subtypes (acute, lymphoma, chronic, and smoldering) associated with different outcomes, and that require different treatment strategies tailored to the clinical presentation. In aggressive ATL (acute and lymphoma subtypes), clinical trials, mostly from Japan, have demonstrated that combinations of chemotherapy can induce acceptable response rates, especially in the lymphoma subtype. However, the overall outcome remains extremely poor owing to a high rate of relapse. Similarly, the so-called indolent forms (smoldering and chronic subtypes) have a poor outcome whether they are managed with watching and waiting or treated with chemotherapy. We recently realized a worldwide meta-analysis and showed that the combination of zidovudine and interferon alpha is highly effective in the leukemic subtypes of ATL and should be considered as standard first-line therapy in that setting. This combination has changed the natural history of the disease through achievement of significantly improved long-term survival in patients with smoldering and chronic ATL as well as a subset of patients with acute ATL. Patients with lymphoma-type ATL still benefit from chemotherapy induction with concurrent or sequential antiretroviral therapy with zidovudine and interferon alpha. Allogeneic stem cell transplantation is a promising option but has several barriers. New drugs such as the new antibody anti-CXCR4 show promising results. Prospective trials testing maintenance therapy in order to avoid relapse are warranted when the patient cannot undergo allogeneic stem cell transplantation. © 2013 Springer Science+Business Media New York.Afonso PV, 2010, BLOOD, V116, P3802, DOI 10.1182-blood-2010-02-270751; Bazarbachi A, 2010, J CLIN ONCOL, V28, P4177, DOI 10.1200-JCO.2010.28.0669; Bazarbachi A, 1999, BLOOD, V93, P278; Bazarbachi A, 1996, J ACQ IMMUN DEF SYND, V13, pS186, DOI 10.1097-00042560-199600001-00028; Coiffier B, 2012, J CLIN ONCOL, V30, P631, DOI 10.1200-JCO.2011.37.4223; Datta A, 2006, BLOOD, V108, P1021, DOI 10.1182-blood-2006-01-0067; Dearden CE, 2001, BLOOD, V98, P1721, DOI 10.1182-blood.V98.6.1721; El Hajj H, 2010, J EXP MED, V207, P2785, DOI 10.1084-jem.20101095; El-Sabban ME, 2000, BLOOD, V96, P2849; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073-pnas.92.9.3963; GILL PS, 1995, NEW ENGL J MED, V332, P1744, DOI 10.1056-NEJM199506293322603; HERMINE O, 1995, NEW ENGL J MED, V332, P1749, DOI 10.1056-NEJM199506293322604; Hermine Olivier, 2002, Hematol J, V3, P276, DOI 10.1038-sj.thj.6200195; Hishizawa M, 2010, BLOOD, V116, P1369, DOI 10.1182-blood-2009-10-247510; Hodson A, 2010, BLOOD, V116; Ishida T, 2012, J CLIN ONCOL, V30, P837, DOI 10.1200-JCO.2011.37.3472; Itonaga H, 2013, BLOOD, V121, P219, DOI 10.1182-blood-2012-07-444372; Kanda J, 2012, BLOOD, V119, P2141, DOI 10.1182-blood-2011-07-368233; Kchour G, 2009, BLOOD, V113, P6528, DOI 10.1182-blood-2009-03-211821; Maeda N, 2010, CANCER SCI, V101, P224, DOI 10.1111-j.1349-7006.2009.01354.x; Marcais A, 2012, LEUK RES TREATMENT, V2012; Mone A, 2005, BLOOD, V106, P3380, DOI 10.1182-blood-2005-01-0335; Moura I, 2011, RETROVIROLOGY, V8, pA60; Nasr R, 2003, BLOOD, V101, P4576, DOI 10.1182-blood-2002-09-2986; Nasr R, 2011, VIRUSES-BASEL, V3, P750, DOI 10.3390-v3060750; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200-JCO.2006.10.2434; Piekarz RL, 2011, BLOOD, V117, P5827, DOI 10.1182-blood-2010-10-312603; Ramos J, 2011, RETROVIROLOGY, V8, pA48; Ravandi F, 2009, J CLIN ONCOL, V27, P5425, DOI 10.1200-JCO.2009.22.6688; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111-j.1365-2141.1991.tb08051.x; SHIMOYAMA M, 1988, J CLIN ONCOL, V6, P1088; Suarez F, 2011, RETROVIROLOGY, V8, pA59; Takasaki Y, 2010, BLOOD, V115, P433; Tsukasaki K, 2003, INT J HEMATOL, V77, P164, DOI 10.1007-BF02983215; Tsukasaki K, 2009, J CLIN ONCOL, V27, P453, DOI 10.1200-JCO.2008.18.2428; Tsukasaki K, 2007, J CLIN ONCOL, V25, P5458, DOI 10.1200-JCO.2007.11.9958; Uike N, 2011, RETROVIROLOGY, V8, pA33; Utsunomiya A, 2011, RETROVIROLOGY, V8, pA40; WALDMANN TA, 1995, BLOOD, V86, P4063; WALDMANN TA, 1993, BLOOD, V82, P1701; White JD, 2001, LEUKEMIA LYMPHOMA, V40, P287, DOI 10.3109-10428190109057927; Whittaker SJ, 2010, J CLIN ONCOL, V28, P4485, DOI 10.1200-JCO.2010.28.9066; Yamada Y, 2001, BRIT J HAEMATOL, V113, P375, DOI 10.1046-j.1365-2141.2001.02737.x46
Management of Relapses After Hematopoietic Cell Transplantation in T-Cell Non-Hodgkin Lymphomas
No full textT-cell non-Hodgkin lymphomas (NHLs) are a heterogeneous group of malignancies that represent 10percent-15percent of all NHLs. The prognosis of relapsed T-cell NHL is poor, especially for those relapsing after an autologous (auto-) or allogeneic (allo-) hematopoietic cell transplantation (HCT). Disease relapse post auto-HCT is best managed on a clinical trial. In the absence of an investigational protocol, the choice of salvage therapies should take into account patient performance status, eligibility for an allo-HCT, and surface CD30 expression. CD30-directed therapies or aggressive salvage regimens can be used as a bridge to allo-HCT in medically fit patients. In the elderly or more infirm patients, single-agent therapies could be offered, aiming at palliation. Similarly, relapse after an allo-HCT is not uncommon and is a real challenge. Reduction in ongoing immune suppression or donor lymphocyte infusion are often considered in this setting to augment graft-versus-lymphoma (GVL) effects and can occasionally provide durable disease control. Clinical trials designed to investigate novel therapeutic agents with immunomodulatory properties to augment GVL effects (eg, histone deacetylase [HDAC] inhibitors, proteasome inhibitor, lenalidomide) or targeted therapies (eg, aurora A kinase inhibitors, anaplastic lymphoma kinase [ALK] inhibitors) are sorely needed to improve the dismal outcomes of T-cell NHL relapsing after an allo-HCT. © 2014 Elsevier Inc.Advani RH, 2012, LEUKEMIA LYMPHOMA, V53, P718, DOI 10.3109-10428194.2011.623256; Arkenau HT, 2007, HAEMATOL-HEMATOL J, V92, P271, DOI 10.3324-haematol.10737; Blum KA, 2010, ANN ONCOL, V21, P2246, DOI 10.1093-annonc-mdq211; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038-nrd2133; Chang ST, 2007, LEUKEMIA LYMPHOMA, V48, P117, DOI 10.1080-10428190601016167; Chen R, 2012, BLOOD, V119, P6379, DOI 10.1182-blood-2012-03-418673; Coiffier B, 2012, J CLIN ONCOL, V30, P631, DOI 10.1200-JCO.2011.37.4223; Coman T, 2013, HAEMATOLOGICA, V98, P776, DOI 10.3324-haematol.2012.069328; Corradini P, 2004, J CLIN ONCOL, V22, P2172, DOI 10.1200-JCO.2004.12.050; Damaj G, 2013, J CLIN ONCOL, V31, P104, DOI 10.1200-JCO.2012.43.7285; d'Amore F, 2010, BRIT J HAEMATOL, V150, P565, DOI 10.1111-j.1365-2141.2010.08298.x; d'Amore F, 2012, J CLIN ONCOL, V30, P3093, DOI 10.1200-JCO.2011.40.2719; Dang NH, 2007, BRIT J HAEMATOL, V136, P439, DOI 10.1111-j.1365-2141.2006.06457.x; Dodero A, 2012, LEUKEMIA, V26, P520, DOI 10.1038-leu.2011.240; Dueck G, 2010, CANCER-AM CANCER SOC, V116, P4541, DOI 10.1002-cncr.25377; Enblad G, 2004, BLOOD, V103, P2920, DOI 10.1182-blood-2003-10-3389; Evens A, 2011, ASH ANN M, V118, P1646; Foss FM, 2011, BLOOD, V117, P6756, DOI 10.1182-blood-2010-05-231548; Friedberg J, 2011, ASH ANN M ABSTR, V118, P95; Gambacorti-Passerini C, 2011, NEW ENGL J MED, V364, P775, DOI 10.1056-NEJMc1013224; Gibb A, 2013, HAEMATOLOGICA, V98, P611, DOI 10.3324-haematol.2012.069393; Goldenberg Marvin M, 2008, P T, V33, P299; Hamadani M, 2008, BIOL BLOOD MARROW TR, V14, P480, DOI [10.1016-j.bbmt.2008.01.002, 10.1016-j.bbnit.2008.01.002]; Horwitz SM, 2012, BLOOD, V119, P4115, DOI 10.1182-blood-2011-11-390211; Iqbal J, 2011, LEUKEMIA, V25, P348, DOI 10.1038-leu.2010.255; Ishida T, 2012, BLOOD, V120, P1734, DOI 10.1182-blood-2012-03-414490; Ishida T, 2012, J CLIN ONCOL, V30, P837, DOI 10.1200-JCO.2011.37.3472; Itonaga H, 2013, BLOOD, V121, P219, DOI 10.1182-blood-2012-07-444372; Iwata S, 2011, INT J CANCER, V129, P2263, DOI 10.1002-ijc.25873; Kanakry JA, 2013, BIOL BLOOD MARROW TR, V19, P602, DOI 10.1016-j.bbmt.2013.01.006; Kim SJ, 2012, INVEST NEW DRUG, V30, P368, DOI 10.1007-s10637-010-9523-2; Kim SW, 2006, BLOOD, V108, P382, DOI 10.1182-blood-2005-02-0596; Kneppers E, 2011, BLOOD, V118, P2413, DOI 10.1182-blood-2011-04-348292; KOLB HJ, 1990, BLOOD, V76, P2462; Koreth J, 2012, J CLIN ONCOL, V30, P3202, DOI 10.1200-JCO.2012.42.0984; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056-NEJMoa1006448; Kyriakou C, 2009, J CLIN ONCOL, V27, P3951, DOI 10.1200-JCO.2008.20.4628; Lee J, 2008, ANN ONCOL, V19, P2079, DOI 10.1093-annonc-mdn431; Le Gouill S, 2008, J CLIN ONCOL, V26, P2264, DOI 10.1200-JCO.2007.14.1366; Leng C, 2006, EXP HEMATOL, V34, P776, DOI 10.1016-j.exphem.2006.02.014; Mak V, 2013, J CLIN ONCOL, V31, P1970, DOI 10.1200-JCO.2012.44.7524; McIver ZA, 2013, BONE MARROW TRANSPL, V48, P1192, DOI 10.1038-bmt.2013.39; Mercadal S, 2008, ANN ONCOL, V19, P958, DOI 10.1093-annonc-mdn022; Mikesch JH, 2013, ANN HEMATOL, V92, P1041, DOI 10.1007-s00277-013-1738-9; Nademanee A, 2011, BIOL BLOOD MARROW TR, V17, P1481, DOI 10.1016-j.bbmt.2011.02.008; O'Mahony D, 2005, ASH ANN M ABSTR, V106, P3353; O'Connor OA, 2011, J CLIN ONCOL, V29, P1182, DOI 10.1200-JCO.2010.29.9024; Ordemann R, 2013, ANN HEMATOL, V92, P125, DOI 10.1007-s00277-012-1524-0; Orlowski RZ, 2007, J CLIN ONCOL, V25, P3892, DOI 10.1200-JCO.2006.10.5460; Pattison NA, 2011, J RELIG HEALTH, V50, P731, DOI 10.1007-s10943-009-9265-7; Pettengell R, 2012, LANCET ONCOL, V13, P696, DOI 10.1016-S1470-2045(12)70212-7; Piccaluga PP, 2007, HAEMATOL-HEMATOL J, V92, P566, DOI 10.3324-haematol.10767; Piekarz RL, 2011, BLOOD, V117, P5827, DOI 10.1182-blood-2010-10-312603; Pohlman B, 2009, ASH ANN M, V114, P920; Pro B, 2012, J CLIN ONCOL, V30, P2190, DOI 10.1200-JCO.2011.38.0402; Puig N, 2013, LEUKEMIA LYMPHOMA, V54, P507, DOI 10.3109-10428194.2012.719615; Qi WQ, 2013, LEUKEMIA RES, V37, P434, DOI 10.1016-j.leukres.2012.10.017; Querfeld C, 2011, LEUKEMIA LYMPHOMA, V52, P1474, DOI 10.3109-10428194.2011.572265; Rasheed W, 2008, EXPERT REV ANTICANC, V8, P413, DOI 10.1586-14737140.8.3.413; Reddy P, 2008, J CLIN INVEST, V118, P2562, DOI 10.1172-JCI34712; Reimer P, 2009, J CLIN ONCOL, V27, P106, DOI 10.1200-JCO.2008.17.4870; Rodriguez J, 2007, HAEMATOL-HEMATOL J, V92, P1067, DOI 10.3324-haematol.11173; Savage KJ, 2011, HEMATOL-AM SOC HEMAT, P515, DOI 10.1182-asheducation-2011.1.515; Savage KJ, 2008, BLOOD, V111, P5496, DOI 10.1182-blood-2008-01-134270; SHIPP MA, 1995, J CLIN ONCOL, V13, P2916; Sibon D, 2012, J CLIN ONCOL, V30, P3939, DOI 10.1200-JCO.2012.42.2345; Singh R, 2012, CLIN CANCER RES, V18, P152, DOI 10.1158-1078-0432.CCR-11-1839; Sockel K, 2012, HAEMATOL-HEMATOL J, V97, pE34, DOI 10.3324-haematol.2012.067629; Sung W, 2013, BIOL BLOOD MARROW TR, V19, pS109; Tan D, 2012, ASH ANN M, V120, P3669; Tomblyn M, 2008, BONE MARROW TRANSPL, V42, P569, DOI 10.1038-bmt.2008.259; Uike N, 2012, ASH ANN M, V120, P2737; Vose JM, 2008, J CLIN ONCOL, V26, P4124, DOI 10.1200-JCO.2008.16.4558; Weidmann E, 2010, LEUKEMIA LYMPHOMA, V51, P447, DOI 10.3109-10428190903580402; Yang DH, 2009, BIOL BLOOD MARROW TR, V15, P118, DOI 10.1016-j.bbmt.2008.11.010; Yao YY, 2013, LEUKEMIA LYMPHOMA, V54, P1194, DOI 10.3109-10428194.2012.739286; Younes A, 2010, NEW ENGL J MED, V363, P1812, DOI 10.1056-NEJMoa1002965; Zhao WL, 2008, BLOOD, V111, P3867, DOI 10.1182-blood-2007-08-108654; Zinzani PL, 2010, ANN ONCOL, V21, P860, DOI 10.1093-annonc-mdp50812
0003
No full textTHE DAILY PALO ALTO TIMES.
jrsn^jrto «to. *!mc-MDATES SET F0R FINAL TENNIS
iMunl *«*)■ ali-riH-.n except Sunday ai
■not)- and Hl*fta Ur-*rt. Palo Alio. Cal.
k**- Co-rt e. -ad Jwicrh H. Tlmnon* r-Btslihcr. |
fo_-.r-.tiuMcontl-cU-i nmi'r, February t-t, j.
I*Wb, at the pu-it ulTl.--; at Palo Alio, California. J
<_d»Um.-|..( CoagTS-SOf M-ath 3, 1ST-*, |
SUBSCKItTlUN KATES:
UM Y**_-r... (Ill Aj-.ai.cj J4.4- i
Sn Maatb* " ■ *«
TMt g-Mlk-L, " .._. I-W '
Oh MiviJ. _._.. _joi
SlO_It Ot-ilct. - — ~ OJ .
B*. Mail or by Carrtt-t
DEBATING TRYOUTS MATCH TOMORROW
Jo*M*r* H Ti-T-,-3
I ll ■■
FRIDAY. OCTOBER 26. 190C.
Abo Ruef at last stands unmasked.
No decent cltlxrn has any excuse now
for 'defense of this trickster who resorts to audacious thwarting of tbe
will of the people in order to save
himself and his tools from prison.
No other explanation of his course
can be made than thai he is frightened and willing to go to any length
to gain ■■ iru temporury advantage
over the men who have blm at bay.
If he ran control tbe grand jury nnd
compel Heney and Burns to disclose
the evidence they have secured, hei
will then be fighting at much better
advantagv than if he remains In the
dark nt to how much tbe enemy
knows. It is inconceivable that
Ruef can Inn-; thwart Justice. In
any case, tb< re can no lunger bo two
sides to the question of l.Uef's baneful intlmi. .-nt man lu
San Friniclsco ought to do all In hi*
power to end tin- shamef .1 conditions
•xistlng In the illy b. driving Ruef
ont of power and into tlie penitentiary.
No sort of professional ethics can
Justify Marshall B. Woodworth In
accepting a farcical deputy-ship under Ruef as a self-created district attorney. A lawyer may take ns it
client a man whom be knows to be
guilty, but this Is not a relationship of attorney nnd client, Ruef]
wants somo one to help him defeat
J us tit-.- and Woodworth must know
that as well as any one. If he con-i
sonts to ally himself with tho graft-j
ing administration at this critical!
point, be will lose the honorable po-
sltion ho has hnd In public esteem.
He will lower himself to tho level j
of the boodlers who are robbing San
Fan Francisco when every man with
a spark of manhood ought to bu
quick to lly to her detenne.
James N. Gillctt is tho plain sort
of man that Inspires confidence. He
haa gained strength daily since he
began his campaign and those who
havo beard him speak aro wilting to
accept the assurances of those who
have known him Intimately that If
elecu-d he will !»■ governor in fact
as well as In name. The controversy
to San Francisco, bringing 1-augdon's
name to the front In connection with
a battle royal against grafters, probably will switch the real contest to
Glllett against Langdon. from GHIeti
against Bell. Nov. L-nngdous only
glory ln the San Francisco affair Is
that be Is willing that Heney should
send Ruef to Jail. He Is not able to
bo tho Joe Folk of San Francisco
yet he would be governor of Califor
nls on a nomination made before h<
had lifted his hand against the graft-
art. If I_angdon had begun the light
months ago that Heney Is now taking
up and If he bad sent Ruef to jail
nnd scattered the grafters, we would
all of us vote for him for governor.
As H la we can vote for Gillctt and
hope for opportunity some day
vote for Heney for governor, when
bo shall havo ruled tbe Rucf gang.
be shall havo routed the Ruef gang.
INTKI'SOClKTY ni'lUTINtl
LBAGUH OP Till-: I'XIVKItSITY
.UtltAXl'lXG FOR ("ONTKSTS.
Fr.".|iiiuiii-S4>|itioii)ore Debate Will
Tiike Place IT*-r***i*nilM*r 8—Carnot
PirHililnarie*-. Am-ugi-d.
At n meeting of thu Intersocloty Debating League of the university th!**
rfternoon dates for the various try-
outs which will be held In the near
f-iti.ro wore set. The tryouts for
tho freshman team which will debate
against the sophomores, will bo hold
Friday evening. November Hith, and
tho sophomore tryouts will take place
tho following crcnlng. W. 11. Tucker, '07, will preside at the first-
named mc«tlng, and F. A. Fisher,
07. wilt be In charge of the sophomore discussion. The Interring* debate hot ween tho teams chosen at
these tryouts will uike place on the
evening ol December Sib. at which
meeting Guy Knupp. '07. will preside. No judges for any of these debates have Wen secured at* jet. but
they will be appointed within the
next few days. All those who Intend
to enter the tryouts who have not
yet handed In their names, are requested to fllo them with W. F. Her-
ron. 'os. as soon as possible.
The preliminary try-out* for the intercollegiate Carnot debate will ho
held X'ovomber 34th. Subjects for
the*** debates will be announced later. It 1b probable that they will deal
wiih conventional subjects, since tbo
general subject of ths Carnot has not
been received as yet. All who expect to enter these tryouts most hand
their names In to Guy Knupp or W.
A, Campbell before November 1st.
-H+hl. 11 1 III i 11 1 111 I ) 11. 1*
(Continued from page one.)
FRESHMAN AND JCNIOR TEAMS
j WILL PI-AY FOR I'NIVI'ltSITY
CHAMPIONSHIP IN IKH'BLI*S.
■ Temil- i:*ilhu*.lii*.(x Anticipate Fast
mid I liter.-.ii ok Contest for Cov-
ted Title.
WANTS
CLASSIFIED
University Express, 171 University
aronue. Phone Black 267. *
Call or pbono for apples (all
kinds), quinces, dried prunes. Comp-
tons. 3t
DRESSMAKINO done very reasonably. Mrs. A. E. Morris, 623 Almi
street
FACTORS TO CONFER
AS TO HANCHETT OFFER
L. E. Hanchett has written J. F.
Parkinson a letter offering to turn
over to any Palo Alto charity he
may name the entire proceeds of the
flrst "day's operation of tho street
ears, and Mr. Parkinson has proposed to turn the matter over to nil
the churches. There will bo a meeting of tho pastors of all the churches
of Palo Alto next Monday afternoon
at 6 o'clock at tbe study of the Con-
grogatlonal Church to confer as to
the details.
" sV
| Wanted—Good delivery man
jdroaa Box "R," Times 3t
Wanted—Young man to go .to
jwork for Palo Alto Gas Company.'
'Good wages; eight hours. 24-tf J
Wanted—Young man to learn toj
[tonka -co cream. Good wages. An-i
ply at Wilson's. 2f-tf
Millinery—Trimming done to order. Materials worked over. 2S3
Homer nvenue. Phone Rod 1'47.
16-lmc
lie university tennis championship in doubles will be decided tomorrow morning on the Encln-i
eourts, beginning ut 9:30. The contestants In the Anal round will be
B. Delano and L. It. Gay, representing tbe class of ■:•"-.. and I.. B.
.Mnckiiy and A. Green, tbe champions
of the freshman class. The match
should be exceedingly Interesting', ff
both teams are in form. Delano und
Gay are players of considerable experience, the former having won the
Thanksgiving handicap tournament
lust year. They had no difficulty in
inning their tryouts, and defeated
Sallbury and Burr, the senior repre-
ntntlvi in a live-set mntcb Wod -
nesday. although both wore In poor
form.
The freshman plnyeds, on the other hand, nre no mean opponents, and
tbelr defeat of Henry and Little In
the tryouts and their subsequent
victory over Gownn, the university
champion In singles, and Adams, his
partner, in the fresh man-sophomore
mutch, occasioned considerable surprise and has caused many tennis enthusiasts to anticipate a victory for
them in the deciding round tomorrow.
The contest will be decided by the
tt-ost three out of five,sets.
Wanted—Room, with facilities
for heating, by young lady; preferably on Campus; permanent. J. I. S.
Times office. 25-31*-
DO YOU WANT MONEY?
If so see the
J. T. 1>UNN INVESTMENT CO-
591 Emerson St.
They have an abundance and will
loan you any amount at market rates,
elthcE flat or investment loan.
Wanted—ln small family, girl for
general housework. Wages, |2u or
* > Inquire S26 University avc-
nuo. 22-lw"
Wanted—Good gont's wheel,
cheap. Address, stating price, R.
Lamb, Postofflce. Menlo Park.
23-lw* j
Wanted—In law office, stenogra- [
pher and typewriter. Address "Stenographer" euro Palo Alto Times, stating experience and coopcnsallon expected. *4tf
II. S. GIBSON
Son Francisco Messenger and Purchasing Agent.
Dally trips. Leaves 9:31 a. m
Agent for Thomas' Dyeing and
Cleaning. Cars Crandall'a Cyclery
Phone Blue 333.
C. DUTHIE COMPANY
Contracting Plasterers
418 Waverly street, phone White
211. Promptness and good workmanship guaranteed.
M. II. Bille
Landscape
gardener
Phone Blue 221.
|
t
Trees, Shrubs. Plants and 9
floods. Experienced men for -.
all branches of work. Contract £
or day work. *»
|
Residence 170 Waverly St
PALO AI/TO, CAL.
4*nf*nf*nf*nf*nf*nf*nfwnf*nf*nf*
interfere with his duties- It declares
that the defendants control the police
department and threaten to eject tbe
plaintiff and seize bis books and records.
It asserts tho each und every one
of the defendants haw been guilty of
felonies and took their action solely
to defeat the ends of Justice und escape punishment.
When the complaint was drafted
it waa Immediately submitted to
Judge Seajvell at bis home. Ho read
it. and forthwith Issued a restraining
order directed against the superv
Ofl and made returnable Friday, November 2d. This order was served
on I'liT-f at bis home. 1900 Vallejo
street. Service wns hnd by Dr. Percy Dolman, wbo found the boss In
his bed. Ruef shied at tbe order,
and for a tlmo would not get up. but
at Inst he rose and accepted service.
.\pl~.int*. Ruef City Attorney.
San Francisco, Oct. 26.—_\bo Ruer
last nlgbt made the Board of Supervisors ''suspend District Attorney
Landgou from his office and appoint
himself to tbe position of District
Attorney of San Francisco.
Immediately Ruef served notice on
Francis J. Heney, the special prosecutor, who has gathered the proof
against Ruef and Mayor Schmltx and
tbe minor members of tho great conspiracy, tbat he was removed from
the office of Deputy District Attorney
and appointed Marshall B. Wood-
worth lu his place.
District Attorney Langdon and
Francis J. Heney refused to accept
] dismissal at such hands and an-
j nouncud that they will coatlnue as
' officers of San Francisco to present
: tbe case against the grafters and will
push the proceedings until the guilty
. are behind tho bars of State Prison.
One of tbe Superrtsors has turned
I State's evidence aad his confession of
| tbo whole long campaign of graft Is
; In Honey's hands. Former Police
Commissioners Reagan, Poboltn and
-Drink ho us** and former Chairman of
; Board of Works Maestrettl, are
named as witnesses tor the prosecution.
, It was the tidings of thu confessions ln the li ii ndn. of Heney that
nerved Ruef to bis desperate move.
Ruef threatens to call Heney and
' Secret Service Agent Burns as his
Drat witnesses when he takes charge
'of.tbe Grand Jury and compel them
|to revoal what they have learned,
i Tho provision of the Charter under
■ which Acting Mayor Gallagher and
the Incriminated Supervisors under
j Ruef'a orders suspended Lnn;*don It
, declared unconstitutional by loading
, lawyers and the court will swiftly
. decide.
' Itiief attacks ex-Mayor Phelnu and
Rudolph Spreckols am!
them with Grand Jury ;■•■
calling them grafters.
Spreckols says Knit's nsurputltm
| of the District Attorney's
confession of guilt ami
olares Ruef thof most
Wanted—Stonogrnpher and typewriter, young man or woman. Address, stating salary expected and experience, P. O. Box 892, Palo Alto,
Cal. 16-tf
PROFESSIONAL
ATTORNEYS.
S. W. CHARLES
FREDERICK SCHNEIDER
Attorneys at Law -
ijo University avenue, Palo Alto,
Cat- Phone Main -**-*.
DENTISTS.
GEO. BLAKESLBY LITTLE
Office, Mad-KW-Tbotts buildinsj,
Pslo Alto, Gal.
A. A. MAC INTYRE,
I). 1). h.. l. t>- H.
Graduate Dental Department, University of Pennsylvania, Phlladsl*
pbla. Post Graduate School of
Prosthetic Dentistry. Atlanta, Georgia. Haskell Post Graduate. Chicago
School ot orthodontia, etc Charges,
reasonable. Ofllce, Lodyard building,
Palo Alto. Hours, 9:30 a. m. to 4:39
p. m.
MEDICAL.
FOB KENT
GEO. H. BENTLEY
Contractor for Plastering
General contractor. All old and
new work. Inside and outside,
promptly attended to. Estimates
given. Resldeuce 665 Hamilton avenue. Phone Rod tit. Percentage
work done,
DR. A. J. VILLAIN,
Physician and Surgeon.
Lata of San Francisco: hours: 1
to 4. and 7 to 8 p. m. OQce and
i'.:ii(ti;m-i;, Hamilton avenue and Ramona street. Palo Alto. Cal. To)
Red 367.
Rooms and Board.
avenue.
Lytton
s-l.-tf
Sunny Front Rooms—With board, ]
319 Alma. 25-lm*
MAXV IXTEHKSTINfi ARTICLES
IN STANFORD ALUMNI S
lU'imissjiiiee of the Stanford Spirit,
by Paul 0. Edward-*, leading
Feature of Month.
The Stanford Alumnus appeared
today and contained a number of features of Interest not only to tbe "old
grads," for whom It Is primarily published, but also to the present student body of tho university. The
leading literary article of the month
is written by Paul C. Edwards, '07,
and is entitled "The Renaissance of
tho Stanford Spirit." The article,
which Is unusually well written,
speaks of the spirit which existed in
the old days, tho days of uncertainty
and of possible defeat, whon students and professors" "wore working
band In band, with a common Impulse, ono ln tbulr pastimes, one In
their work, and Inseparably one in
their anxiety to uphold and upbuild
the fair name of Stanford." Tbe
writer then defines and traces tho
action of the forces which In course
of time led to the drifting apart of
fncut'y -iinl students, and then, ln
I-: ins of glowing optimism, declnros
hat the earthquake, in spile of the
materia) destruction which It
wrought, has been the moans of restoring tho old spirit of unanimity
and friendship. In proof of this
statemont tho author cites the new
regime which has been instituted as
evidenced by tho appointment of the
commission of engineers, the organization of the President's Conference, and the formation of the new
committee on t-tudent'affairs.
Among other features in the Issue
is un article on tho "Alumni Reunion Movement," by H. I. Cruian. '06,
a review of the 190G commencement,
by W. T, Wenti. '06, and a rcatime
of the football season to date, by J.
E. Cushlng, '08.
HUM 11111.1 11 1 I II 1 1 III 1 1 I
criminal that ever disgraced the city.
District Attorney Langdon hav
abandoned bis campaign, leaving his
canvass for tho Governorship In thu
hands of the people, and Is hastening
to San Francisco to confront Rue!
before tbe courts nnd drive him from
the onice he claims.
District Attorney Lam-don and
Francis J. Heney will appenr and gc
ahead with the drawing of (he Grand
Jury this afternoon, whlcb is to consider the charges against the city administration. Ruef wnl also ho there
and Judge Graham will havo to decide at once who Is the District At*
torney of San Francisco.
District Attorney l.«ngdon appoint-
ed Francis J. Heney as Assistant District Attorney to help him lo running
to earth the reports of collosal graft
fn tho administration of tbo city,
With the assistance of Secret Service
Detective Burns It Is said Mr, Heney
has Incriminating and positive evidence against some of the most
prominent officials of tho city, and la
an endeavor to escape i:iv-*-iiilgatiot.
the removal of Mr. Langdon and tin
dismissal of Heney was ordered by
Acting Mayor Gallagher and approved by the Board of Supervisors
at tbo hc-bost of Abo Ruef.
For Rent—Two nice housekeeping
rooms, 808 Wavorly. 26-31*-
For Rent—Housekeeping flat of
four rooms. 625 Emerson. 26-3t
Furnished Rooms—With or without board. 207 Hawthorne avenue.
26-lw»
Sunny *Front Room—Downstairs.
electric light, near Avenue. 440
Cowper street. 10-2w c
Messenger Service
SAN PBANCISCO
Commencing October lit dally
trips: Leavo 9:31 train. All kinds
of business transacted. Leave orders at Fuller's Grocery. Pbona
Main 61, and 266 Channlng. Orders left ln the Messenger Box at
the Campus P. O. will receive prompt
attention.
O. M. ATKINSON.
YOl* WILL NEVER MAKE A
MISTAKE IP YOU ENTRUST THE
To rent with option to boy—Small MOVING OF YOUR GOODS TO US.
payments. 2 now bouses, 6 or 7 j*o\V IS THE TIME TO TEST OUR
rooms- Modern. Just built. Byron
street, just off Lytton. Also satto ABILITY TO SAVE YOU MONEY
or rooms, 533 Homer Ave. A. W.'*jfj) GIVE YOU FULL 8ATISFAC-
*-■"■ """"""" *** "••• , j.-.-.*. WITH ?UB WOBK. IT
For Rent—Farm of 85 acres; plen-■ WOULD BE IMPRUDENT FOR
ty of water on both -Ides of ranch; |yo|. TO MJgs T|IIg oppoRTUKmr
largo barn for 6 horses and 12 cows, i
with room for 100 tons of hay: house!OP ENTRUSTING YOUR TRASFER
of 11 rooms, hard finished; best BUSINESS TO US.
placo on coast for chicken raining; j
two mites from Mayfleld on Page
mill road. Mra. Murphy. 10-2S-lm'
FOR SALE.
A 1600 Piano—Net
•iPalo Alto Transfer Co.
525 ALMA STREET
Phone Main P0
For Sale— Fresh cow and calf, f t
170 Bryant street. Phone Blue 263. \ £
I
For Snle^—Thoroughbred bronze j*
turkeys, thoroughbred barred Plym- i
outh hens and pullets. Mrs. J. E
iBh, Santa Rita avenue, below May-
field. 17-2wc
For Sale—Finest buy and investment property ln Palo Alto, 112,600.
Investigate and be convinced. No
agents- No trlfler-a. Owner, P. O.
Box 93. 9-1 m c
LOST
Hallowe'en
Apples
9
f
Hallowe'en In almost here. .*»
1-iy In a stock of rosy apples, 9
nuts and and pumpkin* for a *
* good night's fun. You will find «!
* onr counters loaded with the )rf
£ best ln tlie market.
Fuller ® Co.
Lost—Moonstone breastpin. cIub-[
ter. valued as u keepsake. Finder'
kindly return to S01 Waverly street.;
Reward. 25-St c
Lost—On University nvenue, a'
chamois purse containing sixty-one.
odd dollars. Finder please return toj
Miss E. M. Krumbeck,'266 Unlver-,1-1
ty avenue. 20-tf {
9
nf**)!* nf**f*nf*'*f*n!*;nf*J*!*n!*
MIKCKLLANI.OI K.
Bread delivered dally. Ft-esb,
;ur.- and wholesome. Del Monte
Bakery. Phone I nil-r A Co., Main
Mra. M. J. Gatts will reopen ber!
dressmaking parlors at 319 Alma SL
Phono Rod 276. . 28-lm*
1'1'HK MILK AND CREAM delivered daily by tbe Palo Alto Cream-;
ery- *.
HAlRDRESSING, scalp treatment,
j manicuring, electric and vibratory
i facial massage, shampooing.- Mi_*
! M. E- Foley, Room 7, Marten
h-iildtog. Telephone Red 391.
I '
Subscribe for The Times.
can hardly be expected from Imperfectly prepared prescriptions or oi
those dispensed from Inferior or i
ond rate materials. With your next
prescription try tbe
STORE OP QUALITY
note tbe results which you obtain,
and particularly rots our prices.
UNIVERSITY DRUG CO.
Fraternity Hall BtiMdln*
PkMM Jams* 61
JOHN O. VARIAN
SdentLnc Massage and Mechanical
Vibration*,
Physicians commend his treatment
Hours, li to 13, I to s-Jto, 7 to I
Telephone Red 150.
DR. WILLARD C. BEAN
Osteopathic Physician.
ELECTRICITY, ELECTRIC LIGHT
BATHS.
Monday. Wednesday and Friday;
evenings by appointment, 460 High
street, noar University avenue, Palo
Alto.
Tuesday, Thursday and Saturday:
evenings by appointment, 1903 Dc~
vlsadero street, corner Pino, San
Francisco.
Telephone West ftr.27.
OSTEOPATHIC
PHYSICIAN
DR. H. C PHELPS
Graduate American School of Osteopathy. Klrkvllle, Ho. 126 University avenue, Crandall Building.
Hours 9 a. tn. to 6 p. m. Phone
Main 79. Examinations free. Treatments given patients at home If de-
sred. Lady attendant at the offloe
at all hours.
MISCELLANEOUS.
O. H. Mm-MKKKIN
Piano Tuner ana Repsdrcr
Formerly of Sherman, Clay A Co., Is
located permanently at 621 Everett
avenue. Palo Alto, and guarantoea
satisfaction In all piano work. Including the polishing of piano cases
HrtITT SCHOOL FOR BOYS
11U1 I 1 Menlo Park, Cat
Lost but three days on account of
earthquake**. Thirty-third semester
opens August 27, 1906. Address
Principal. W. J. Meredith.
Miss Kllzabeth Hoghcs, A. B., M. 8.
Tutoring In Preparatory Braneoee-
1248 Waverly St., Tel. Rod 81.
KINDERGARTEN
1028 Rryant Street
.Mrs. II. H. Jackson, Principal,
Miiw Flora Rice, Asaltant Teacher.
Children at a distance conveyed to
and from school.,
MISS SUSIE McGOWAN,
(Formerly of Stroxynskl A Co.
San Francisco.)
Halrdresslng. Manicuring, Stumpoo-
-*■*--. Scalp Trvatim-m. Facial Masaagtr-
and Singring.
MO Emerson Street- near
University Avenne-
MISS M. GEARY
Dressmaker
Sowing at home or by the day,
329 Hawthorno avenue, Palo Alto,
Cal
Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial
No full textBackground: Initial results from the ongoing GALLIUM trial have shown that patients with follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy with obinutuzumab than with rituximab. The aim of this secondary analysis was to evaluate the prognostic value of PET–CT responses after first-line immunochemotherapy in the GALLIUM study. Methods: GALLIUM is an open-label, parallel-group randomised, phase 3 trial, which recruited previously untreated patients with CD20-positive follicular lymphoma (grades 1–3a; disease stage III/IV, or stage II with largest tumour diameter ≥7 cm) who were aged 18 years or older and met the criteria for needing treatment. Eligible patients were randomly assigned in a 1:1 ratio to receive intravenous administration of obinutuzumab (1000 mg on days 1, 8, and 15 of cycle 1, then day 1 of subsequent cycles) or rituximab (375 mg/m2 on day 1 of each cycle), in six 21-day cycles with cyclophosphamide, doxorubicin, vincristine, and prednisone (known as CHOP; oral administration) followed by two 21-day cycles of antibody alone, or eight 21-day cycles cyclophosphamide, vincristine, and prednisone (known as CVP; oral administration), or six 28-day cycles with bendamustine, followed by maintenance antibody every 2 months for up to 2 years. The primary endpoint of the trial, investigator-assessed progression-free survival, has been reported previously. This secondary analysis reports PET and CT-based responses at end-of-induction therapy and explains their relation with progression-free and overall survival outcomes in patients with available scans. As per protocol, during the trial, PET scans (mandatory in the first 170 patients enrolled at sites with available PET facilities, and optional thereafter), acquired at baseline and end of induction (PET population), were assessed prospectively by investigators and an independent review committee (IRC) applying International Harmonisation Project (IHP) 2007 response criteria, and retrospectively by the IRC only applying current Lugano 2014 response criteria. IRC members (but not study investigators) were masked to treatment and clinical outcome when assessing response. The landmark analyses excluded patients who died or progressed (contrast enhanced CT-based assessment of progressive disease, or started next anti-lymphoma treatment) before or at end of induction. GALLIUM is registered at ClinicalTrials.gov, number NCT01332968. Findings: 1202 patients were enrolled in GALLIUM between July 6, 2011, and Feb 4, 2014, of whom 595 were included in the PET population; 533 (IHP 2007; prospective analysis), and 508 (Lugano 2014; retrospective analysis) were analysed for progression-free survival (landmark analysis). At end of induction, 390 of 595 patients (65·5% [95% CI 61·6–69·4]) achieved PET complete response according to IHP 2007 criteria, and 450 (75·6% [95% CI 72·0–79·0]) obtained PET complete metabolic response according to Lugano 2014 criteria. With a median of 43·3 months of observation (IQR 36·2–51·8), 2·5-year progression-free survival from end of induction was 87·8% (95% CI 83·9–90·8) in PET complete responders and 72·0% (63·1–79·0) in non-complete responders according to IRC-assessed IHP 2007 criteria (hazard ratio [HR] 0·4, 95% CI 0·3–0·6, p<0·0001). According to Lugano 2014 criteria, 2·5-year progression-free survival in complete metabolic responders was 87·4% (95% CI 83·7–90·2) and in non-complete metabolic responders was 54·9% (40·5–67·3; HR 0·2, 95% CI 0·1–0·3, p<0·0001). Interpretation: Our results suggest that PET is a better imaging modality than contrast-enhanced CT for response assessment after first-line immunochemotherapy in patients with follicular lymphoma. PET assessment according to Lugano 2014 response criteria provides a platform for investigation of response-adapted therapeutic approaches. Additional supportive data are welcomed. Funding: F Hoffmann-La Roche
